This white paper examines the Philippines' growing role as a strategic destination for global oncology clinical trials. Drawing on a nationwide survey of investigators, site capabilities, and clinical trial experience, IQVIA highlights the country's high burden of cancers such as breast, lung, colorectal, liver, and cervical cancer, along with a large population of late-stage patients suitable for Phase II–III and biomarker-driven studies. The paper explores investigator readiness, precision oncology infrastructure, biomarker testing, regulatory considerations, and patient recruitment dynamics. It concludes that the Philippines offers high-quality research capabilities, strong patient engagement, and expanding clinical infrastructure, making it an attractive location for sponsors seeking f

Join for free to read